Sentinel node biopsy examination for breast cancer in a routine laboratory practice: Results of a pilot study

Asian Pacific Journal of Cancer Prevention

Volumn 17, Issue 3, 2016, Pages 1149-1155

  Khoo, Joon Joon ^a   Ng, Chen Siew ^b   Sabaratnam, Subathra ^a   Arulanantham, Sarojah ^c  

^a MONASH UNIVERSITY MALAYSIA   (Malaysia)

^b HOSPITAL SULTANAH AMINAH   (Malaysia)

^c Sultan Ismail Hospital   (Malaysia)

Author keywords

Breast carcinoma; Immunohistochemical validation; Sentinel lymph nodes; Serial sectioning; Thin slicing

Indexed keywords

ADULT; AGED; AXILLA; BREAST NEOPLASMS; CANCER STAGING; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE; LYMPH NODE METASTASIS; MICROMETASTASIS; MIDDLE AGED; PATHOLOGY; PILOT STUDY; PROGNOSIS; PROSPECTIVE STUDY; SECONDARY; SENTINEL LYMPH NODE BIOPSY; TUMOR INVASION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AXILLA; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM MICROMETASTASIS; NEOPLASM STAGING; PILOT PROJECTS; PROGNOSIS; PROSPECTIVE STUDIES; SENTINEL LYMPH NODE BIOPSY;

EID: 84965081603     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2016.17.3.1149     Document Type: Article

References (72)

1. Abdollahi A, Jangjoo A, Dabbagh Kakhki VR, et al (2010). Factors affecting sentinel lymph node detection failure in breast cancer patients using intradermal injection of the tracer. Rev Esp Med Nucl, 29, 73-7
2. Albertini JJ, Lyman GH, Cox C, et al (1996). Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA, 276, 1818-22
3. Amir AS, Azar FP, Sahram N, et al (2012). Prevalence of occult metastases in axillary sentinel lymph nodes of breast carcinoma. Pol J Pathol, 63, 40-4
4. Amoui M, Akbari ME, Tajeddini A, et al (2012). Value of sentinel lymph node biopsy in breast cancer surgery with simple pathology facilities-an Iranian local experience with a review of potential causes of false negative results. Asian Pac J Cancer Prev, 13, 5385-9
5. Andersson Y, Frisell J, Sylvan M, et al (2013). Causes of false-negative sentinel node biopsy in patients with breast cancer. Br J Surg, 100, 775-83
6. Andersson Y, Frisell J, Sylvan M, et al (2010). Breast cancer survival in relation to the metastatic tumor burden in axillary lymph nodes. J Clin Oncol, 28, 2868-73
7. Barnwell JM, Arredondo MA, Kollmorgen D, et al (1998). Sentinel node biopsy in breast cancer. Ann Surg Oncol, 5, 126-30
8. Borgstein PJ, Pijpers R, Comans EF, et al (1998). Sentinel lymph node biopsy in breast cancer: guidelines and pitfalls of lymphoscintigraphy and gamma probe detection. J Am Coll Surg, 186, 275-83
9. Chagpar A, Pilavas J, Chao C, et al (2003). Sentinel lymph node biopsy for breast cancer:addressing the controversies. Cancer Therapy, 1, 223-32
10. Chu KU, Turner RR, Hansen NM, et al (1999). Do all patients with sentinel node metastasis from breast carcinoma need complete axillary node dissection? Ann Surg, 229, 536-41
11. Cody HSR, Hill AD, Tran KN, et al (1999). Credentialing for breast lymphatic mapping: how many cases are enough? Ann Surg, 229, 723-6
12. Cox CE, Bass SS, McCann CR, et al (2000). Lymphatic mapping and sentinel lymph node biopsy in patients with breast cancer. Annu Rev Med, 51, 525-42
13. Cserni G (1999). Metastases in axillary sentinel lymph nodes in breast cancer as detected by intensive histopathological work up. J Clin Pathol, 52, 922-4
14. Cserni G, Gregori D, Merletti F, et al (2004). Meta-analysis of non-sentinel node metastases associated with micrometastatic sentinel nodes in breast cancer. Br J Surg, 91, 1245-52
15. Dauway EL, Giuliano R, Haddad F, et al (1999). Lymphatic mapping in breast cancer. Hematol Oncol Clin North Am, 13, 349-71
16. de Boer M, van Dijck JA, Bult P, et al (2010). Breast cancer prognosis and occult lymph node metastases, isolated tumour cells and micrometastases. J Natl Cancer Inst, 102, 410-25
17. Dowlatshahi K, Fan M, Snider HC, et al (1997). Lymph node micrometastases from breast carcinoma: reviewing the dilemma. Cancer, 80, 1188-97
18. Ellis IO (2005). Pathology reporting of breast disease. In 'NHS Breast Screening Programme (NHSBSP) publication. NHS Cancer Screening Programmes and The Royal College of Pathologists.', Eds Publication No.58. London
19. Ensani F, Enayati L, Rajabiani A, et al (2013). Improved detection of metastases by step sectioning and immuno-histochemical staining of axillary sentinel nodes in patients with breast carcinoma. Asian Pac J Cancer Prev, 14, 5731-4
20. Fancellu A, Cottu P, Feo CF, et al (2012). Sentinel node biopsy in early breast cancer: lessons learned from more than 1000 cases at a single institution. Tumori, 98, 413-20
21. Fitzgibbons PL, Page DL, Weaver D, et al (2000). Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med, 124, 966-78
22. Fréneaux P, Nos C, Vincent-Salomon A, et al (2002). Histological detection of minimal metastatic involvement in axillary sentinel nodes: a rational basis for a sensitive methodology usable in daily practice. Mod Pathol, 15, 641-6
23. Gill J, Lovegrove R, Naessens K, et al (2011). Sentinel lymph node biopsy in breast cancer: an analysis of the maximum number of nodes requiring excision. Breast J, 17, 3-8
24. Giuliano AE, Dale PS, Turner RR, et al (1995). Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg, 222, 394-401
25. Giuliano AE, Jones RC, Brennan M, et al (1997). Sentinel lymphadenectomy in breast cancer. J Clin Oncol, 15, 2345-50
26. Giuliano AE, Kirgan DM, Guenther JM, et al (1994). Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg, 220, 391-401
27. Gobardhan PD, Elias SG, Madsen EV, et al (2009). Prognostic value of micrometastases in sentinel lymph nodes of patients with breast carcinoma: a cohort study. Ann Oncol, 20, 41-8
28. Goyal A, Newcombe RG, Chhabra A, et al (2006). Factors affecting failed localisation and false-negative rates of sentinel node biopsy in breast cancer-results of the ALMANAC validation phase. Breast Cancer Res Treat, 99, 203-8
29. Grabau D, Ryden L, Fernö et al (2011). Analysis of sentinel node biopsy -a single-institution experience supporting the use of serial sectioning and immunohistochemistry for detection of micrometastases by comparing four different histopathological laboratory protocols. Histopathol, 59, 129-38
30. Groen RS, Oosterhuis AW, Boers JE (2007). Pathologic examination of sentinel lymph nodes in breast cancer by a single haematoxylin-eosin slide versus serial sectioning and immunocytokeratin staining: clinical implications. Breast Cancer Res Treat, 105, 1-5
31. Huvos A, Hutter R, Berg J (1971). Significance of axillary macrometastases and micrometastases in mammary cancer. Ann Surg, 173, 44-6
32. Jakub JW, Pendas S, Reintgen DS (2003). Current status of sentinel lymph node mapping and biopsy: facts and controversies. Oncologist, 8, 59-68
33. Jannink I, Fan M, Nagy S, et al (1998). Serial sectioning of sentinel nodes in patients with breast cancer: a pilot study. Ann Surg Oncol, 5, 310-4
34. Kamath VJ, Giuliano R, Dauway EL, et al (2001). Characteristics of the sentinel lymph node in breast cancer predict further involvement of higher-echelon nodes in the Axilla. Arch Surg, 136, 688-92
35. Keskek M, Balas S, Gokoz A, et al (2006). Re-evaluation of axillary skip metastases in the era of sentinel lymph node biopsy in breast cancer. Surg Today, 36, 1047-52
36. Kim T, Giuliano AE, Lyman GH (2006). Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. Cancer, 106, 4-16
37. Koslow SB, Eisenberg RE, Qiu Q, et al (2014_. Sentinel lymph node biopsy is a reliable method for lymph node evaluation in neoadjuvant chemotherapy-treated patients with breast cancer. Am Surg, 80, 171-7
38. Krag D, Weaver D, Ashikaga T, et al (1998). The sentinel node in breast cancer-a multicenter validation study. N Engl J Med, 339, 941-6
39. Krag DN, Anderson SJ, Julian TB, et al (2007). Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol, 8, 881-8
40. Lee AHS, Ellis IO, Pinder SE, et al (2000). Pathological assessment of sentinel lymph-node biopsies in patients with breast cancer. Virchows Arch, 436, 97-101
41. Liberman L (2000). Pathologic analysis of sentinel lymph nodes in breast carcinoma. Cancer, 88, 971-7
42. Lin PP, Allison DC, Wainstock J, et al (1993). Impact of axillary lymph node dissection on the therapy of breast cancer patients. J Clin Oncol, 11, 1536-44
43. Lyman GH, Giuliano AE, Somerfield MR, et al (2005). American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol, 23, 7703-20
44. Madsen EV, Elias SG, van Dalen T, et al (2013). Predictive factors of isolated tumor cells and micrometastases in axillary lymph nodes in breast cancer. Breast, 22, 748-52
45. Martin RC, Chagpar A, Scoggins CR, et al (2005). Clinicopathologic factors associated with false-negative sentinel lymph-node biopsy in breast cancer. Ann Surg, 241, 1005-12
46. McMasters KM, Tuttle TM, Carlson DJ, et al (2000). Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used. J Clin Oncol, 18, 2560-6
47. National. Coordinating. Group.for. Breast. Screening. Pathology 1997. Pathology reporting in breast cancer screening, Sheffield:NHSBSP Publications
48. Patani N, Mokbel K (2011). Clinical significance of sentinel lymph node isolated tumour cells in breast cancer. Breast Cancer Res Treat, 127, 325-34
49. Pendas S, Dauway EL, Giuliani R, et al (2000). Sentinel node biopsy in ductal carcinoma in situ patients. Ann Surg Oncol, 7, 15-20
50. Reintgen DS, Haddad F, Pendas S, et al (1998). Lymphatic mapping and sentinel lymph node biopsy. Sci Am, 17, 1-17
51. Snider H, Dowlatshahi K, Fan M, et al (1999). Sentinel node biopsy in staging of breast cancer. Am J Surg, 176, 305-10
52. Straver ME, Meijnen P, van Tienhoven G, et al (2010). Sentinel node identification rate and nodal involvement in the EORTC 10981-22023 AMAROS trial. Ann Surg Oncol, 17, 1854-61
53. Sun J, Yin J, Ning L, et al (2012). Clinicopathological characteristics of breast cancers with axillary skip metastases. J Invest Surg, 25, 33-6
54. Tafra L, Lannin DR, Swanson MS, et al (2001). Multicenter trial of sentinel node biopsy for breast cancer using both technetium sulfur colloid and isosulfan blue dye. Ann Surg, 233, 51-9
55. Tai P, Joseph KJ, Yu E (2011). Issues related to sentinel lymph node assessment in the management of breast cancer-what are relevant in pathology reports? Patholog Res Int, 2011
56. Torrenga H, Rahusen FD, Meijer S, et al (2001). Sentinel node investigation in breast cancer; detailed analysis of the yield from step sectioning and immunohistochemistry. J Clin Pathol, 54, 550-2
57. Turner RR, Ollila DW, Krasne DL, et al (1997). Histopathologic validation of the sentinel lymph node hypothesis for breast carcinoma. Ann Surg, 226, 271-8
58. Turner RR, Ollila DW, Stern S, et al (1999). Optimal histopathologic examination of the sentinel lymph node for breast carcinoma staging. Am J Surg Pathol, 23, 263-7
59. van Diest PJ (1999). Histopathological workup of sentinel lymph nodes: how much is enough? J Clin Pathol, 52, 871-3
60. van Diest PJ, Peterse HL, Borgstein PJ, et al (1999). Pathological investigation of sentinel lymph nodes. Eur J Nucl Med, 26, 43-9
61. Verma R, Rajan SS, Verghese ET, et al (2014). Pathological evaluation of the staging axillary lymph nodes for breast cancer: a national survey in the United Kingdom. Histopathol, 65, 707-11
62. Veronesi U, Paganelli G, Galimberti V, et al (1997). Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet, 349, 1864-7
63. Veronesi U, Paganelli G, Viale G, et al (1999). Sentinel lymph node biopsy and axillary dissection in breast cancer: results in a large series. J Natl Cancer Inst, 91, 368-73
64. Veronesi U, Paganelli G, Viale G, et al (2003). A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med, 349, 546-53
65. Vijayakumar V, Boerner PS, Jani AB, et al (2005). A critical review of variables affecting the accuracy and false-negative rate of sentinel node biopsy procedures in early breast cancer. Nucl Med Commun, 26, 395-405
66. Weaver D, Krag DN, Manna EA, et al (2002). Comparison of occult micrometastasis detection in breast caner sentinel lymph nodes using manual cytokeratin immunohistochemistry and image analysis. Mod Pathol, 15, 55A-6A
67. Weaver DL (2010). Pathology evaluation of sentinel lymph nodes in breast cancer: protocol recommendations and rationale. Mod Pathol, 23, 26-32
68. Weaver DL, Krag DN, Ashikaga T, et al (2000). Pathologic analysis of sentinel and nonsentinel lymph nodes in breast carcinoma: a multicenter study. Cancer, 88, 1099-107
69. Wilking N, Rutqvist LE, Carstensen J, et al (1992). Prognostic significance of axillary nodal status in primary breast cancer in relation to the number of resected nodes. Stockholm Breast Cancer Study Group. Acta Oncol, 31, 29-35
70. Wong SL, Edwards MJ, Chao C, et al (2001a). The effect of lymphatic tumor burden on sentinel lymph node biopsy results. Breast J, 8, 192-8
71. Wong SL, Edwards MJ, Chao C, et al (2001b). Sentinel lymph node biopsy for breast cancer: impact of the number of sentinel nodes removed on the false-negative rate. J Am Coll Surg, 192, 684-9
72. Zakaria S, Degnim AC, Kleer CG, et al (2007). Sentinel lymph node biopsy for breast cancer: how many nodes are enough? J Surg Oncol, 96, 554-9